Clinical Trial

Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 6, 2021 (before its estimated January 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is designed to verify the safety and efficacy of Lepu® NeoVas™ Bioabsorbable Coronary Artery Rapamycin-eluting Stent System combined with different antiplatelet therapies in the treatment of coronary heart disease.
Trial Details
NCT Number NCT04995159
Lead Sponsor Lepu Medical Technology (Beijing) Co., Ltd.
Conditions Coronary Heart Disease
Enrollment 2,150 participants
Start Date 2021-09
Primary Completion 2026-01 (estimated)
Study Completion 2028-01 (estimated)
Updated on ClinicalTrials.gov 2021-08-06